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Many a science writer has fantasized
about capping a story with the
headline “Good News for Sick
Mice!” One of the toughest struggles
is deciding how to cover a story that
has produced tantalizing, even
amazing, results in laboratory animals
but could well be a total bust by the
time it gets to humans.
That issue came up in early July,
when Elan Pharmaceuticals, an Irish
company with laboratories in South
San Francisco, announced a vaccine
that is remarkably effective at
treating Alzheimer’s-like symptoms
in a genetically engineered strain of
mouse. These mice don’t get
Alzheimer’s or severe mental
impairment — or even the brain
‘tangles’ characteristic of the disease.
They do, however, develop amyloid
plaques, which are present in many,
but not all, brains ravaged by
Alzheimer’s disease. The company’s
experimental vaccine vanquished the
plaques, at least in a handful of mice.
That result was published in Nature,
and reporters were left to decide how
to handle the announcement.
The Washington Post and Los Angeles
Times considered the news marginal
enough to rate a few paragraphs
buried deep in the paper. But many
others took the bait and dusted off a
word that’s all but taboo among US
science writers: “Breakthrough.” And
television in particular attacked this
story with relish. “We are going to
begin tonight with the very best
news there has been in many years,
perhaps ever, about one of the most
debilitating chronic diseases that
haunts us,” Peter Jennings told his
audience on ABC’s World News
Tonight. The report was long on
excitement about this “breakthrough”
and short on caution. It was also a bit
confused on some of the basic facts,
declaring that “one in 10 people who
suffer from Alzheimer’s is over 65.”
Other broadcasters also leaped for
the “breakthrough” word, including
CBS’s This Morning. Putting the best
possible spin on the story, this report
interviewed an official from the
Alzheimer’s Association — whose job
is to raise money for research. “We’re
going to benefit from this no matter
whether it works in humans or not,”
said Bill Thies. “It’s going to give us
very important information.”
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And that word “breakthrough” crept
up in reports by the (London)
Independent, the Sacramento Bee, and
the Tampa Tribune. New Scientist didn’t
use the ‘B’ word, but reached instead
for the even more dangerous ‘C’ word
by declaring: “A cure for Alzheimer’s
might be within the grasp of
researchers at a Californian company.”
The Express (London) managed to
use both “cure” and “breakthrough”
in its opening paragraphs.
Christine Gorman at Time
Magazine was much more
philosophical about the “possible
breakthrough.” Under the headline
“Hope Meets Hype,” Gorman said
“This is the hardest kind of story for
me to write. It’s about real advances
in basic research on Alzheimer’s.”
She went on to describe the horrors
of the disease — and the real
limitations of this kind of research.
Her sober, albeit colorless,
conclusion is, “The most important
thing to take away from this research
news is that it’s a ‘proof of concept’,
as scientists call it.”
The New York Times mixed equal
parts of optimism and caution in its
story, which ran deep in the paper.
The report quoted an enthusiastic
official from the Alzheimer’s
Association and then declared “This
is the first time the association has
expressed optimism about any
pharmaceutical development in
treating or preventing the disease.”
But to dampen that excitement, the
report also noted, “It remains to be
seen if the compound will produce
the same effects in people. Indeed, it
remains to be seen if it improves
cognition even in mice, which is
difficult to measure.”
One paper managed to strike a
magic balance — putting the story on
the front page without overselling
the results. The Wall Street Journal
report had this strong lead: “When a
researcher at a small California drug
company first suggested vaccinating
people against Alzheimer’s disease,
his fellow scientists thought the idea
nutty enough to put it on an office
bulletin board of outlandish
comments.” The story then
proceeded to weave this personable
tale in with a broader development:
several drug companies are gambling
on products that could affect amyloid
plaques in Alzheimer’s patients.
The Irish Times noted apparent
serendipity in the timing of Elan’s
news. The paper reported that, earlier
in the week, the pharmaceutical
company had been publicly rebuked
by the US Securities and Exchange
Commission for accounting practices,
“which, it felt, inflated reported
earnings.” The mouse announcement
apparently stemmed a slide in the
company’s stock value triggered by
the SEC letter.
Of course, nobody ended up
declaring that the whole business is
simply good news for sick mice. But
a writer for the San Francisco
Chronicle settled on the next best
thing — a metaphor that sounds
encouraging yet is utterly
ambiguous. The report called the
results “a new turn” in the battle
against Alzheimer’s. The metaphor is
particularly apt for California drivers,
who are accustomed to driving on
mountainous roads with seemingly
endless turns and bends.
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